Strongbridge Biopharma: Commercial stage company focused on rare diseases. Topline placebo-controlled Ph3 LOGICS data expected Q3 for RECORLEV™, cortisol synthesis inhibitor for endogenous Cushing's syndrome. Enrollment completion announced May 11, 2020. KEVEYIS® is first and only approved drug for Primary Periodic Paralysis (PPP); Q1'20 revenue up 54% from Q1'19 and guiding to FY20 revenue of $22M-$26M.
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Central Nervous System, Rare Disease
Public, USA
Market Cap
100MM - 500MM
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Top 10 Holders of Strongbridge Biopharma plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Caxton Corp. 14.88 8,060,682 17.09 Stakes 9/18/20
NEA Management Co. 7.64 4,141,308 8.78 13F 6/30/20
Ikarian Capital LLC 6.04 3,271,238 6.94 13F 6/30/20
The Vanguard Group, Inc. 3.37 1,824,054 3.87 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 3.30 1,785,952 3.79 13F 6/30/20
Morgan Stanley Smith Barney LLC 2.47 1,339,172 2.84 13F 6/30/20
Renaissance Technologies LLC 2.32 1,254,600 2.66 13F 6/30/20
BlackRock Fund Advisors 2.30 1,248,232 2.65 13F 6/30/20
Hudson Bay Capital Management LP 2.24 1,213,139 2.57 13F 6/30/20
State Street Corp. 1.36 737,303 1.56 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.